News & AnalysisJanux Therapeutics amasses $56m Series AJanux Therapeutics, a developer of immunotherapies, has secured $56 million in Series A financing.ByIris Dorbian3 March 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs